The company said worldwide sales for the fiscal third quarter were $22.5 billion, up 5.2%, including operational growth of 6.3% and a negative currency impact of 1.1%. Johnson & Johnson said worldwide sales for the fiscal nine months rose 4.0% to $66.3 billion.

10-QQuarterly reportFiled Oct 23, 2024Period of report Sep 29, 2024Summary published (UTC) Oct 23, 2026

Key points

AI summary

The company said worldwide sales for the fiscal third quarter were $22.5 billion, up 5.2%, including operational growth of 6.3% and a negative currency impact of 1.1%. Johnson & Johnson said worldwide sales for the fiscal nine months rose 4.0% to $66.3 billion.
Johnson & Johnson said Innovative Medicine segment sales for the fiscal third quarter rose 4.9% to $14.6 billion. The company cited an unfavorable patient mix and share loss in Europe due to biosimilar entrants as factors reducing STELARA sales in Immunology.
The company said consolidated earnings before provision for taxes on income for the fiscal third quarter were $3.3 billion, or 14.9% of sales, compared with $5.2 billion, or 24.4%, a year earlier. It also said the quarter included NM26 bispecific antibody global rights acquisition expense of $1.25 billion and talc-related charges of $2.0 billion.
The company said cash, cash equivalents and marketable securities totaled about $20.3 billion as of September 29, 2024, while notes payable and long-term debt were about $35.8 billion, leaving net debt of $15.5 billion. It said the net proceeds of the $6.7 billion senior unsecured notes issued in the fiscal second quarter were used for the Shockwave acquisition and general corporate purposes.

Key figures

Quarter ended September 29, 2024

Revenue: $22.5B
Net income: $2.7B
EPS: $1.11
Gross profit: $15.5B

From the XBRL financial data filed with the SEC · not processed by AI.

Summary

AI-written

Analysis scope · Management's discussion (MD&A)We analyzed excerpts of the Management's Discussion and Analysis (MD&A) section (with omissions). Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.

Third quarter and nine-month worldwide sales

The company said worldwide sales for the fiscal third quarter were $22.5 billion, up 5.2%, including operational growth of 6.3% and a negative currency impact of 1.1%. Johnson & Johnson said worldwide sales for the fiscal nine months rose 4.0% to $66.3 billion.

Source · Based on the MD&A text of the filing

Innovative Medicine and STELARA

Johnson & Johnson said Innovative Medicine segment sales for the fiscal third quarter rose 4.9% to $14.6 billion. The company cited an unfavorable patient mix and share loss in Europe due to biosimilar entrants as factors reducing STELARA sales in Immunology.

Source · Based on the MD&A text of the filing

Pre-tax earnings and NM26 and talc items

The company said consolidated earnings before provision for taxes on income for the fiscal third quarter were $3.3 billion, or 14.9% of sales, compared with $5.2 billion, or 24.4%, a year earlier. It also said the quarter included NM26 bispecific antibody global rights acquisition expense of $1.25 billion and talc-related charges of $2.0 billion.

Source · Based on the MD&A text of the filing

Cash and debt balances

The company said cash, cash equivalents and marketable securities totaled about $20.3 billion as of September 29, 2024, while notes payable and long-term debt were about $35.8 billion, leaving net debt of $15.5 billion. It said the net proceeds of the $6.7 billion senior unsecured notes issued in the fiscal second quarter were used for the Shockwave acquisition and general corporate purposes.

Source · Based on the MD&A text of the filing

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.

View the original filing on SEC EDGAR ↗

Unauthorized scraping, data storage and database creation prohibited

Without prior written consent, you must not crawl or scrape data compiled and organized by Chickstock or its analysis and summaries, or collect them repeatedly or in bulk for storage, ingestion or database creation. Repurposing, redistribution, sale and use to build other services are also prohibited.

Unauthorized use may result in access restrictions, demands to stop infringement and delete copies, and claims for damages. Violations of applicable law may also give rise to criminal liability.

Uses permitted by law, the Terms of Service or a separate agreement remain subject to their respective scope. Rights in individual source materials, including original filings, remain with their respective rights holders.